万孚生物上半年净利1.89亿元，同比下降46.82%

Core Viewpoint - Wanfu Biological (300482) reported a significant decline in both revenue and net profit for the first half of 2025, indicating potential challenges in the in vitro diagnostic sector [1] Financial Performance - The company achieved a revenue of 1.246 billion yuan in the first half of 2025, representing a year-on-year decrease of 20.92% [1] - The net profit attributable to shareholders was 189 million yuan, down 46.82% compared to the same period last year [1] Business Focus - Wanfu Biological primarily operates in the medical device sector, specifically in the field of in vitro diagnostics, focusing on the research, development, production, and marketing of rapid diagnostic reagents and supporting instruments [1]